Use of arsenic trioxide in a hemodialysis-dependent patient with relapsed acute promyelocytic leukemia
Perreault S, Moeller J, Patel K, Eyler R, Pham T, Russell K, Podoltsev N. Use of arsenic trioxide in a hemodialysis-dependent patient with relapsed acute promyelocytic leukemia. Journal Of Oncology Pharmacy Practice 2015, 22: 646-651. PMID: 25972392, DOI: 10.1177/1078155215586235.Peer-Reviewed Original ResearchMeSH KeywordsAged, 80 and overAntineoplastic AgentsArsenic TrioxideArsenicalsDrug MonitoringHumansKidney Failure, ChronicLeukemia, Promyelocytic, AcuteMaleOxidesRenal DialysisConceptsHemodialysis-dependent patientsAcute promyelocytic leukemiaArsenic trioxidePromyelocytic leukemiaPre-existing cardiac conditionsRelapsed acute promyelocytic leukemiaSevere renal impairmentFront-line treatmentPaucity of dataRenal impairmentDialysis patientsDose adjustmentHemodialysis patientsCardiac conditionsPatientsThree timesLeukemiaRegimenDialysisImpairmentMarginal amount